MAPT and Alzheimer disease: Over the past decade, the most prevalent pharmacological categories currently investigated as candidate strategies for the treatment of AD included neurotransmitter enhancers (11.38%), anti-Amyloid agents (13.30%), multi-target drugs (2.45%), anti-Tau agents (2.03%), and diverse natural products (25.58%).